Sector Experts

Jason Kolbert

Maxim Group

Image: Jason Kolbert

Jason Kolbert has worked extensively in the healthcare sector as product manager for a leading pharmaceutical company, as a fund manager and as an equity analyst. Prior to joining Maxim Group, where he is head of healthcare research, senior managing director and biotechnology analyst, Kolbert spent seven years at Susquehanna International Group, where he managed a healthcare fund and founded SIG's biotechnology team. Previously, Kolbert served as the healthcare strategist for Salomon Smith Barney. He is often quoted in the media and is a sought-out expert in the biotechnology field. Prior to beginning his Wall Street career, Kolbert served as a product manager for Schering-Plough in Osaka, Japan. He received a bachelor's degree in chemistry from State University of New York, New Paltz, and a master's degree in business administration from the University of New Haven.




Recent Interviews

How Did High Flyers Turn into Soul Searchers? Maxim Analyst Jason Kolbert on the Highs and Lows of Biotech Valuations (4/2/14) After soaring more than 56% last year, the NASDAQ Biotechnology Index is down almost 15% in March. In this interview with The Life Sciences Report, Jason Kolbert of the Maxim Group points to increased approval rates and a better economic and regulatory environment as the fundamentals behind a revaluation that has occurred in the sector. Kolbert also reflects on recent concerns about pricing and policy changes that have triggered what he considers a normal, healthy correction in an otherwise robust and intact sector.

The New Year Heralds a Transition in Stem Cell Development: Jason Kolbert (12/17/13) The cell therapy industry has been mired in phase 1 and 2 studies for what seems like a lifetime. But 2014 is shaping up to be a banner year for share-moving phase 2 data and pivotal phase 3 activity. Jason Kolbert, managing director for biotechnology research at Maxim Group, leverages his deep understanding of the stem cell space to uncover viable therapies that double as excellent business models. In this interview with The Life Sciences Report, Kolbert guides investors to regenerative medicine companies that have evolved beyond great science projects into businesses capable of generating huge margins and disrupting the paradigm of medical practice.

Is Cell Therapy the 'Future of Medicine'?: Jason Kolbert (7/25/13) The pricey evolutionary tradeoff for walking on two legs is the curse of lower back pain. Jason Kolbert of the Maxim Group understands the power of stem cells as disease-modifying therapies for degenerative disc disease of the spine, a leading-edge, multibillion-dollar indication. Kolbert explores the opportunities that cell therapies offer investors in this interview with The Life Sciences Report, and puts a personal spin on their regenerative promise.

Recent Quotes

"We are initiating coverage on DMPI with a Buy rating." (4/2/14) DelMar Pharmaceuticals Inc. - Jason Kolbert, Maxim Group Moreá>

"ATHX's MultiStem has the potential to completely change existing treatment paradigms." (4/2/14) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

"For INO, the probability of a positive VGX-3100 trial outcome is rising." (3/18/14) Inovio Pharmaceuticals Inc. - Jason Kolbert, Maxim Group Moreá>

"One area where ATHX shines is the quality of the science." (3/17/14) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

"Positive data from either of its clinical trials could mean a major value increase for ATHX." (3/14/14) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

"STEM received authorization to expand its SCI trial into Canada." (3/13/14) StemCells Inc. - Jason Kolbert, Maxim Group Moreá>

"We believe 2014 could be a major year of transition for CYTX." (3/12/14) Cytori Therapeutics Inc. - Jason Kolbert, Maxim Group Moreá>

"The potential of the OMER MASP-2 antibody is significant." (3/11/14) Omeros Corp. - Jason Kolbert, Maxim Group Moreá>

more comments

"PSTI's manufacturing position is likely to translate into a key competitive advantage." (3/6/14) Pluristem Therapeutics Inc. - Jason Kolbert, Maxim Group Moreá>

"MSB finished 2013 with ample cash and just received pivotal FDA approval for its Resvascor trial." (2/26/14) Mesoblast Ltd. - Jason Kolbert, Maxim Group Moreá>

"OMER's pipeline progress looks good." (2/5/14) Omeros Corp. - Jason Kolbert, Maxim Group Moreá>

"CYTX is moving to create additional indications with clear endpoints." (2/3/14) Cytori Therapeutics Inc. - Jason Kolbert, Maxim Group Moreá>

"We would not be surprised to see a major device company partner with MSB." (1/30/14) Mesoblast Ltd. - Jason Kolbert, Maxim Group Moreá>

"We expect to see followup data soon from MSB's phase 2 DDD trial." (1/27/14) Mesoblast Ltd. - Jason Kolbert, Maxim Group Moreá>

"Last year, INO's data continued to validate its platform technology." (1/27/14) Inovio Pharmaceuticals Inc. - Jason Kolbert, Maxim Group Moreá>

"PSTI's manufacturing position should be a key competitive advantage." (1/23/14) Pluristem Therapeutics Inc. - Jason Kolbert, Maxim Group Moreá>

"PSTI is advancing placental expanded cells on multiple fronts." (1/21/14) Pluristem Therapeutics Inc. - Jason Kolbert, Maxim Group Moreá>

"Data from ATHX's phase 2 clinical trial are expected by mid-April." (1/6/14) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

"The bottom line is that good data become transformative for ATHX." (12/19/13) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

"We'd love to see MSB launch a U.S. clinical trial with Prochymal in graft-versus-host disease, where an approved therapy is so desperately needed." (12/17/13) Mesoblast Ltd. - The Life Sciences Report Interview with Jason Kolbert Moreá>

"When you think about the number of opportunities that exist for a company like INO, it's almost limitless." (12/17/13) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>

"CYTX operates its own subsidiary in Japan, and probably has the largest presence of any cell therapy company in that country." (12/17/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>

"I very much believe the results of NBS' trial will be positive." (12/17/13) NeoStem Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>

"If ATHX can enroll a handful of Japanese patients to be part of the current phase 2 trial, that could create an accelerated pathway to the marketplace." (12/17/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>

"The Intrexon partnership parallels SYN's expertise and portfolio." (12/10/13) Synthetic Biologics Inc. - Jason Kolbert, Maxim Group Moreá>

"New study data show MSB's stem cells are active, safe and effective." (12/4/13) Mesoblast Ltd. - Jason Kolbert, Maxim Group Moreá>

"In the heart failure space and among the autologous players, we believe ATHX cells are among the most potent." (11/20/13) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

"We see MSB as the undisputed leader in the congestive heart failure space." (11/20/13) Mesoblast Ltd. - Jason Kolbert, Maxim Group Moreá>

"The CYTX business model is quite strong." (11/20/13) Cytori Therapeutics Inc. - Jason Kolbert, Maxim Group Moreá>

"CUR expects to commence its phase 1/2 trial in China in Q4/13." (11/18/13) Neuralstem Inc. - Jason Kolbert, Maxim Group Moreá>

"An MSB trial showed MPCs enhanced sensorimotor recovery in rats." (11/18/13) Mesoblast Ltd. - Jason Kolbert, Maxim Group Moreá>

"ATHX's phase 2 trial is the most important one to watch in the space." (11/18/13) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

"ATHX's valuation could be significantly higher if data are compelling." (11/15/13) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

"We see Trimesta for multiple sclerosis as the principal driver for SYN." (11/14/13) Synthetic Biologics Inc. - Jason Kolbert, Maxim Group Moreá>

"CYTX represents the best of both autologous and allogeneic worlds." (11/11/13) Cytori Therapeutics Inc. - Jason Kolbert, Maxim Group Moreá>

"The FDA has approved MSB's commencement of its phase 3 trial." (10/31/13) Mesoblast Ltd. - Jason Kolbert, Maxim Group Moreá>

"We see great strategic value in MSB's latest news about Japan." (10/28/13) Mesoblast Ltd. - Jason Kolbert, Maxim Group Moreá>

"MSB's entrÚe into oncology is exciting." (10/23/13) Mesoblast Ltd. - Jason Kolbert, Maxim Group Moreá>

(10/14/13) Mesoblast Ltd. - Jason Kolbert, Maxim Group Moreá>

"Strong data should translate into an IMUC valuation near our metrics." (10/3/13) ImmunoCellular Therapeutics Ltd. - Jason Kolbert, Maxim Group Moreá>

"We are initiating coverage of SYN with a Buy rating." (9/30/13) Synthetic Biologics Inc. - Jason Kolbert, Maxim Group Moreá>

"We are pleased to see SNGX's story developing again with positive news flow." (9/25/13) Soligenix Inc. - Jason Kolbert, Maxim Group Moreá>

"The quality of INO's platform attracted Roche Holding AG to the recently announced partnership." (9/25/13) Inovio Pharmaceuticals Inc. - Jason Kolbert, Maxim Group Moreá>

"CYTX's ATHENA trials are building critical mass." (9/18/13) Cytori Therapeutics Inc. - Jason Kolbert, Maxim Group Moreá>

"With the release of clinical hold, PSTI can now make headway on multiple fronts." (9/16/13) Pluristem Therapeutics Inc. - Jason Kolbert, Maxim Group Moreá>

"ATHX is close to reporting data, which could be transformative." (8/14/13) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

"CYTX continues to make great progress in Japan." (8/9/13) Cytori Therapeutics Inc. - Jason Kolbert, Maxim Group Moreá>

"BRTX has developed a very interesting, unique cannula that seems to work extremely well." (7/25/13) BioRestorative Therapies Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>

"We see ATHX's valuation as compelling." (7/9/13) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

"The way that STEM is going about its clinical trials and developing its product and cell line has been brilliant." (5/10/13) StemCells Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>

"IMUC is one of my favorites." (5/10/13) ImmunoCellular Therapeutics Ltd. - The Life Sciences Report Interview with Jason Kolbert Moreá>

"CYTX shines because it provides the best of both worlds, an autologous process with allogeneic-like cost of goods sold." (5/10/13) Cytori Therapeutics Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>

"MBLTY is the leader in the stem cell space." (5/10/13) Mesoblast Ltd. - The Life Sciences Report Interview with Jason Kolbert Moreá>

"ATHX is a neat little company that has a great management team and deep science bench." (5/10/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>

"With ATHX'S active phase 2 trial in stroke, we see the potential for a rapid pathway to marketplace." (4/19/13) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

"We see ATHX's valuation as compelling." (3/22/13) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

"ATHX has one of the best manufacturing processes in allogeneic cell therapy I've ever seen." (3/14/13) Athersys Inc. - The Life Sciences Report Interview with Jason Kolbert Moreá>

"STEM's spine cord trial has now officially been expanded to the U.S. and Canada." (1/8/13) StemCells Inc. - Jason Kolbert, Maxim Group Moreá>

"ATHX has a strong balance sheet and deeply attractive EV." (11/12/12) Athersys Inc. - Jason Kolbert, Maxim Group Moreá>

fewer comments


Due to permission requirements, not all quotes are shown.